p53 expression in synovial sarcoma and its association with prognostic factors
Background: Synovial sarcoma is an aggressive tumor and has two common histological subtype, biphasic and monophasic. It has SYT-SSX gene fusion that decreases expression of p53 tumor suppressor. The prognosis is associated with mitosis and tumor diameter. Therefore this study conducted to know the pattern of p53 expresion and its association with mitosis, histological subtype, and other prognosis factors.
Methods: Twenty synovial sarcoma cases consisted of 4 monophasic and 16 biphasic cases from Cipto Mangunkusumo Hospital-Faculty of Medicine, Universitas Indonesia (CMHospital-FMUI) 2005-2011 were analyzed for association of p53 expression and mitosis as prognostic factor. Haematoxylin-eosin slides were used to count mitosis. Paraffin block materials were used to analyze p53 expression by immunohistochemistry and to detect SYT gene translocation by FISH (Fluorescein in situ Hybridization).
Results: The Fisher's exact test showed that positive p53 expression was associated with tumor diameter <5 cm although it was not associated with mitosis. The histological subtype has no association with p53 expression and mitosis. Unfortunately, only 7/19 cases were positive for FISH-SYT gene translocation.
Conclusion: In synovial sarcoma, p53 expression is associated with tumor diameter. (Med J Indones. 2012;21:196-202)
World Health Organization. International agency for research on cancer. Fletcher C. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008;97(4):314-20. https://doi.org/10.1002/jso.20974
Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res. 2008;466(9):2156-67. https://doi.org/10.1007/s11999-008-0340-2
D'Arcy P, Maruwge W, Ryan BA, Brodin B. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Mol Cancer Res. 2008;6(1):127-38. https://doi.org/10.1158/1541-7786.MCR-07-0176
Robbins S. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia PA: Saunders/Elsevier; 2010.
Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol [Internet]. 2011;2011:[about 13 p]. Available from: http://www.hindawi.com/journals/biomed/2011/603925/. https://doi.org/10.1155/2011/603925
Abramoff M, Magelhaes P, Ram S. Image processing with ImageJ. Biophotonics International. 2004;11(7):36-42.
Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol. 2000;13(9):994-1004. https://doi.org/10.1038/modpathol.3880180
Amary MFC, Berisha F, Bernardi FDC, Herbert A, James M, Reis-Filho JS, et al. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol. 2007;20(4):482-96. https://doi.org/10.1038/modpathol.3800761
Fang Z, Chen J, Teng S, Chen Y, Xue R. Analysis of soft tissue sarcomas in 1118 cases. Chin Med J. 2009;122(1):51-3.
Schneider-Stock R, Onnasch D, Haeckel C, Mellin W, Franke D-S, Roessner A. Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Archiv. 1999;435(4):407-12. https://doi.org/10.1007/s004280050418
Oda Y, Tsuneyoshi M. Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and molecular target therapy in the future. Cancer Sci. 2009;100(2):200-8. https://doi.org/10.1111/j.1349-7006.2008.01024.x
Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14(17):5318-24. https://doi.org/10.1158/1078-0432.CCR-07-5136
Monoclonal mouse anti-human p53 protein, clone DO-7 [Internet]. [cited 2012 Jun 1]. Available from: http://www.dako.com/dist/ar38/p105510/prod_products.htm?setCountry=true&purl=ar38/p105510/prod_products.htm.
Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol [Internet]. 2011;2011:[about 7 p]. Available from: http://www.hindawi.com/journals/biomed/2011/978312/. https://doi.org/10.1155/2011/978312
Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N, Eimoto T. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol. 2000;13(5):482-8. https://doi.org/10.1038/modpathol.3880083
Przybyl J, Jurkowska M, Rutkowski P, Debiec-Rychter M, Siedlecki JA. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma [Internet]. 2012;2012:[about 13 p]. Available from: http://www.hindawi.com/journals/srcm/2012/249219/. https://doi.org/10.1155/2012/249219
Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107. https://doi.org/10.1038/nrc2584
Bruce R P. Recent advances in the molecular diagnosis of paediatric soft tissue sarcomas. Diagnostic Histopathology. 2011;17(1):25-35. https://doi.org/10.1016/j.mpdhp.2010.10.003
Motoi T, Kumagai A, Tsuji K, Imamura T, Fukusato T. Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma. Hum Pathol. 2010;41(10):1397-404. https://doi.org/10.1016/j.humpath.2010.02.009
Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10(5):437-49. https://doi.org/10.1016/j.ccr.2006.09.013
Bhargava R, Shia J, Hummer AJ, Thaler HT, Tornos C, Soslow RA. Distinction of endometrial stromal sarcomas from "hemangiopericytomatous" tumors using a panel of immunohistochemical stains. Mod Pathol. 2005;18(1):40-7. https://doi.org/10.1038/modpathol.3800248
Copyright (c) 2012 Muhammad I. Ilmiawan, Puspita E. Wuyung, Nurjati C. Siregar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.